Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 9/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416093 | 0.83 | L3MBTL1 (0.35) | ELANEHTR6DYRK1AKDM4EALDH1A1 | |
| SCHEMBL12147051 | 0.81 | KDM4E (0.46) | KDM4EALDH1A1CYP2C19SMN1; SMN2 | |
| SCHEMBL12500888 | 0.78 | ELANE (0.39) | ELANEKDM4E | |
| SCHEMBL15091644 | 0.78 | CTSB (0.40) | ELANEDYRK1AMAOAMAOBKDM4E | |
| SCHEMBL4569767 | 0.78 | DYRK1A (0.50) | ELANEHTR6DYRK1AHTR2AHTR2C | |
| SCHEMBL21294169 | 0.77 | ELANE (0.41) | ELANEHTR6DYRK1AHTR2AHTR2C | |
| SCHEMBL12146931 | 0.77 | ELANE (0.39) | ELANEHTR6DYRK1AHTR2AHTR2C | |
| SCHEMBL415786 | 0.76 | HDAC3 (0.38) | KAT2BSMN1; SMN2 | |
| SCHEMBL413117 | 0.76 | L3MBTL1 (0.40) | HTR6ALDH1A1CYP3A4TSHR | |
| SCHEMBL12147002 | 0.76 | HTR2A (0.30) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-3088400-A1 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | PLEXXIKON, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1755597-A2 | AZAINDOLES MODULATING C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060058340-A1 | Compounds modulating c-kit activity | PLEXXIKON INC. | 2006-03-16 | — | — | US | disclosed |
| US-20060058339-A1 | Compounds modulating c-kit activity and uses therefor | PLEXXIKON, INC. | 2006-03-16 | — | — | US | disclosed |
| WO-2006009755-A2 | AZAINDOLES MODULATING C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006009797-A1 | AZAINDOLES MODULATING C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | ELANE 1793/4885HTR6 917/4885DYRK1A 3201/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | ELANE 3585/4885HTR6 4013/4885DYRK1A 604/4885 |
| US-20060058340-A1 | Compounds modulating c-kit activity | KIT, CDC7, CDK7 | ELANE 4050/4885HTR6 389/4885DYRK1A 1356/4885 |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | RET, FGFR1, FGFR3 | ELANE 3118/4885HTR6 3342/4885DYRK1A 750/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | ELANE 3585/4885HTR6 4013/4885DYRK1A 604/4885 |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | ELANE 2195/4885HTR6 981/4885DYRK1A 3186/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | ELANE 1940/4885HTR6 2314/4885DYRK1A 1666/4885 |
| US-20060058339-A1 | Compounds modulating c-kit activity and uses therefor | KIT, APC, RET | ELANE 4188/4885HTR6 910/4885DYRK1A 1716/4885 |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | KIT, FLT3, FLT1 | ELANE 2016/4885HTR6 849/4885DYRK1A 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.